$ENTO
Entero Therapeutics Inc

2024 Q2 Form 10-Q Financial Statement

#000141057824000826 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.207M $8.660M $2.701M
YoY Change 13.36% 220.64% -38.7%
% of Gross Profit
Research & Development $219.6K $566.0K $1.362M
YoY Change -83.77% -58.44% -72.64%
% of Gross Profit
Depreciation & Amortization $5.500K $12.29K $7.300K
YoY Change -24.66% 68.4% -0.23%
% of Gross Profit
Operating Expenses $3.426M $9.226M $4.062M
YoY Change -18.07% 127.1% -56.7%
Operating Profit -$3.426M -$9.226M -$4.062M
YoY Change -18.07% 127.1% -56.7%
Interest Expense $220.00 $66.20K $8.987K
YoY Change -95.75% 636.64% 60.34%
% of Operating Profit
Other Income/Expense, Net -$4.114K -$66.63K -$8.228K
YoY Change -45.78% 709.76% -96.64%
Pretax Income -$3.430M -$9.292M -$4.071M
YoY Change -18.12% 128.28% -57.72%
Income Tax $4.255M -$14.90M
% Of Pretax Income
Net Earnings -$8.808M $5.568M -$4.071M
YoY Change 110.25% -236.77% -57.72%
Net Earnings / Revenue
Basic Earnings Per Share -$3.86 $3.12 -$1.82
Diluted Earnings Per Share -$3.86 $0.38 -$1.82
COMMON SHARES
Basic Shares Outstanding 2.475M 2.025M 1.550M
Diluted Shares Outstanding 2.294M 14.51M 2.281M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $662.5K $3.432M $2.064M
YoY Change -46.4% 66.24% -63.75%
Cash & Equivalents $700.0K $3.400M $2.100M
Short-Term Investments
Other Short-Term Assets $83.72M $4.058M $1.445M
YoY Change 7390.51% 180.75% 74.75%
Inventory
Prepaid Expenses $554.4K $4.058M $1.445M
Receivables $20.00K
Other Receivables
Total Short-Term Assets $84.39M $7.490M $3.530M
YoY Change 3485.15% 112.19% -46.11%
LONG-TERM ASSETS
Property, Plant & Equipment $1.335K $25.75K $36.52K
YoY Change -95.43% -29.5% -44.49%
Goodwill $1.684M $20.04M $1.684M
YoY Change 0.0% 1089.81% -9.55%
Intangibles $63.37M
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.27K $32.77K $39.67K
YoY Change 62.56% -17.39% 15.32%
Total Long-Term Assets $1.901M $83.64M $2.004M
YoY Change -3.73% 4073.63% -11.92%
TOTAL ASSETS
Total Short-Term Assets $84.39M $7.490M $3.530M
Total Long-Term Assets $1.901M $83.64M $2.004M
Total Assets $86.29M $91.13M $5.534M
YoY Change 1893.76% 1546.81% -37.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.014M $1.997M $469.8K
YoY Change 26.57% 325.01% -86.38%
Accrued Expenses $1.822M $2.554M $845.7K
YoY Change 279.79% 202.04% 17.87%
Deferred Revenue
YoY Change
Short-Term Debt $177.6K $386.8K $380.4K
YoY Change 15.69% 1.68% -5.56%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.38M $6.173M $2.625M
YoY Change 371.74% 135.18% -81.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $6.398M $0.00
YoY Change
Other Long-Term Liabilities $101.0K $127.6K $196.5K
YoY Change -45.28% -35.08% -94.89%
Total Long-Term Liabilities $101.0K $6.398M $196.5K
YoY Change -45.28% 3155.59% -94.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.38M $6.173M $2.625M
Total Long-Term Liabilities $101.0K $6.398M $196.5K
Total Liabilities $15.49M $13.27M $2.821M
YoY Change 349.4% 370.34% -84.38%
SHAREHOLDERS EQUITY
Retained Earnings -$187.6M -$178.8M -$172.6M
YoY Change 6.11% 3.59% 5.57%
Common Stock $294.00 $203.00 $155.00
YoY Change -30.17% 30.97% -92.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.121M $16.18M $2.713M
YoY Change
Total Liabilities & Shareholders Equity $86.29M $91.13M $5.534M
YoY Change 1893.76% 1546.81% -37.3%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$8.808M $5.568M -$4.071M
YoY Change 110.25% -236.77% -57.72%
Depreciation, Depletion And Amortization $5.500K $12.29K $7.300K
YoY Change -24.66% 68.4% -0.23%
Cash From Operating Activities -$3.451M -$3.747M -$2.846M
YoY Change 24.96% 31.68% -64.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $88.17K
YoY Change
Cash From Investing Activities $0.00 $88.17K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 681.4K 3.379M 3.547M
YoY Change -64.75% -4.74% -33.91%
NET CHANGE
Cash From Operating Activities -3.451M -3.747M -2.846M
Cash From Investing Activities 0.000 88.17K
Cash From Financing Activities 681.4K 3.379M 3.547M
Net Change In Cash -2.769M -279.9K 701.5K
YoY Change 234.32% -139.89% -127.57%
FREE CASH FLOW
Cash From Operating Activities -$3.451M -$3.747M -$2.846M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2025208
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
First Wave BioPharma, Inc.
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604191
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2025208
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37853
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road, Suite 502
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
CY2024Q1 dei City Area Code
CityAreaCode
561
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
589-7020
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
FWBI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2475090
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3431913
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3711770
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4058053
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1244466
CY2024Q1 us-gaap Assets Current
AssetsCurrent
7489966
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4956236
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25749
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
21522
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
21522
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365486
CY2024Q1 fwbi Research And Development In Processes
ResearchAndDevelopmentInProcesses
63000000
CY2024Q1 us-gaap Goodwill
Goodwill
20038508
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
181421
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
195440
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2024Q1 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
83618187
CY2023Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1912394
CY2024Q1 us-gaap Assets
Assets
91133902
CY2023Q4 us-gaap Assets
Assets
6883195
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1996519
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
554277
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2554446
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2024Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
1135760
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
1069616
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
386769
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
612784
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
71216
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67111
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
28546
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4239
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6173256
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3133317
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6397889
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
571221
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
127592
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146949
CY2024Q1 us-gaap Liabilities
Liabilities
13269958
CY2023Q4 us-gaap Liabilities
Liabilities
3280266
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
61681100
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2025208
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
203
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
156
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
194943707
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187931445
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178761066
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184328672
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
16182844
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91133902
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6883195
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
565962
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1361683
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8659692
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2700742
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
9225654
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4062425
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9225654
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4062425
CY2024Q1 us-gaap Interest Expense
InterestExpense
66202
CY2023Q1 us-gaap Interest Expense
InterestExpense
8987
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
228
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1873
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-653
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1114
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-66627
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8228
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9292281
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4070653
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-14859887
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
5567606
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4070653
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
66144
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
87431
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5501462
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4158084
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761953
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114033
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14511461
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114033
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.12
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-36.46
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.38
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-36.46
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
CY2024Q1 fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
3604936
CY2024Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2300500
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
120648
CY2024Q1 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
9
CY2024Q1 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
66144
CY2024Q1 fwbi Stock And Warrants Issued During Period Value Issued For Services
StockAndWarrantsIssuedDuringPeriodValueIssuedForServices
781000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271360
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
5567606
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
16182844
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023Q1 fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
3769911
CY2023Q1 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
301
CY2023Q1 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
87431
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358316
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4070653
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2712596
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
5567606
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4070653
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12293
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7318
CY2024Q1 fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
18251
CY2023Q1 fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
15528
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
271360
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
358316
CY2024Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
781000
CY2024Q1 fwbi Issuance Of Common Stock To Financial Advisors At Acquisition
IssuanceOfCommonStockToFinancialAdvisorsAtAcquisition
120648
CY2024Q1 fwbi Issuance Of Preferred Stock To Financial Advisors At Acquisition
IssuanceOfPreferredStockToFinancialAdvisorsAtAcquisition
3890626
CY2024Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
14859887
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-73014
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-318342
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-511393
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-18863
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-15751
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
526033
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-250280
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-398672
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
525552
CY2024Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
24307
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-15
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3746956
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2845578
CY2024Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
88169
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
88169
CY2024Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3604936
CY2023Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3769911
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
301
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
226015
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
223104
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3378930
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3547108
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-279857
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
701530
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3733292
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3453435
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2085953
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
21969
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
8987
CY2024Q1 fwbi Fair Value Of Common Shares Issued In Acquisition Net Of Cash
FairValueOfCommonSharesIssuedInAcquisitionNetOfCash
-152331
CY2024Q1 fwbi Fair Value Of Preferred Stock Issued In Acquisition Net Of Cash
FairValueOfPreferredStockIssuedInAcquisitionNetOfCash
-57790474
CY2024Q1 fwbi Options Assumed
OptionsAssumed
-1271000
CY2024Q1 fwbi Warrants Assumed
WarrantsAssumed
-789000
CY2024Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
66144
CY2023Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
87431
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178800000
CY2024Q1 fwbi Working Capital Deficiency
WorkingCapitalDeficiency
1300000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2023Q4 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
20
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At March 31, 2024 the Company had approximately $3.4 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p>
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3400000
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q1 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
386769
CY2023Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
612784
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
106781
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
81032
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
73253
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25749
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2024Q1 us-gaap Depreciation
Depreciation
7779
CY2023Q1 us-gaap Depreciation
Depreciation
7300
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
18354326
CY2024Q1 us-gaap Goodwill
Goodwill
20038508
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-4514
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365486
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
63365486
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
81250
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
108333
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
52917
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
38333
CY2024Q1 fwbi Finite Lived Intangible Asset Expected Amortization After Year Three
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearThree
84653
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365486
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1328669
CY2024Q1 fwbi Consulting Fees
ConsultingFees
662947
CY2023Q4 fwbi Consulting Fees
ConsultingFees
75972
CY2024Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
507844
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
253577
CY2024Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
54986
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
495741
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2554446
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2025208
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2024Q1 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1000
CY2023Q1 fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
148
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1779780
CY2023Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
19.29
CY2023 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y11M26D
CY2024Q1 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
878150
CY2024Q1 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
4.48
CY2024Q1 fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y11M4D
CY2024Q1 fwbi Class Of Warrant Or Right Shares Assumed From Business Acquisition
ClassOfWarrantOrRightSharesAssumedFromBusinessAcquisition
127680
CY2024Q1 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Assumed From Business Acquisition
ClassOfWarrantOrRightWeightedAverageExercisePriceAssumedFromBusinessAcquisition
3.48
CY2024Q1 fwbi Class Of Warrant Or Right Assumed Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightAssumedWeightedAverageRemainingContractualTerm
P8Y11M19D
CY2024Q1 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
83525
CY2024Q1 fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y11M4D
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2702085
CY2024Q1 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
14.32
CY2024Q1 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108797
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
383.20
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
CY2023Q1 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
147053
CY2023Q1 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
51.00
CY2023Q1 fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y11M15D
CY2023Q1 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
21473
CY2023Q1 fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P5Y3M10D
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
234377
CY2023Q1 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
210.00
CY2023Q1 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y25D
CY2024Q1 fwbi Class Of Warrant Or Right Shares Assumed From Business Acquisition
ClassOfWarrantOrRightSharesAssumedFromBusinessAcquisition
127680
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271360
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358316
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
600000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2024Q1 fwbi Number Of Real Property Operating Leases
NumberOfRealPropertyOperatingLeases
2
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
35000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
37000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
67308
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
88788
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
60593
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
216689
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17881
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
198808
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
7246629
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
461971
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
6784658
CY2024Q1 us-gaap Debt Current
DebtCurrent
386769
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6397889
CY2024Q1 fwbi Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsShares
269000
CY2023Q1 fwbi Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsShares
44750
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5501462
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
66144
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5567606
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1761953
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14511461
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.38
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15397069
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
242980
CY2024Q1 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.06
CY2024Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
37000
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
26000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
1.60
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-14900000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000826-index-headers.html Edgar Link pending
0001410578-24-000826-index.html Edgar Link pending
0001410578-24-000826.txt Edgar Link pending
0001410578-24-000826-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fwbi-20240331.xsd Edgar Link pending
fwbi-20240331x10q.htm Edgar Link pending
fwbi-20240331xex31d1.htm Edgar Link pending
fwbi-20240331xex31d2.htm Edgar Link pending
fwbi-20240331xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
fwbi-20240331_cal.xml Edgar Link unprocessable
fwbi-20240331_lab.xml Edgar Link unprocessable
fwbi-20240331_pre.xml Edgar Link unprocessable
fwbi-20240331x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
fwbi-20240331_def.xml Edgar Link unprocessable